BioCentury
ARTICLE | Clinical News

Oglufanide disodium: Phase IIa started

September 3, 2007 7:00 AM UTC

The company began an open-label Phase IIa trial in 20 patients to evaluate 0.1 mg/day of intranasal oglufanide disodium for 21 days. ...